MT-201 – Deep Vein Thrombosis, Pulmonary Embolism

A fully humanized antibody that, unlike conventional clotting cascade inhibitors, targets a novel regulator of thrombosis

Provides a non-bleeding antithrombotic effect, with preclinical data confirming both thrombus prevention and thrombus resolution

Venous thromboembolism (VTE): Over 10 million cases annually worldwide, a leading cause of death
Pulmonary embolism (PE): Acute mortality rates up to 30%, while bleeding risks of current anticoagulants limit long-term use

The global anticoagulant market exceeds $50B annually.

MT-201 is positioned as a novel-target, non-bleeding antibody therapy, poised to emerge as a next-generation antithrombotic option
with distinct competitiveness